Details of the Drug Combinations

General Information of This Drug (ID: DMT6E5N)

Drug Name

ONAPRISTONE DMT6E5N

Synonyms

Onapristone; 96346-61-1; Onapristone [INN]; ZK-98299; Onapristonum [Latin]; Onapristona [Spanish]; UNII-H6H7G23O3N; ZK 299; CCRIS 6530; ZK 98299; ZK-299; H6H7G23O3N; C29H39NO3; Onapristone (INN); Onapristonum; Onapristona; (8S,11R,13R,14S,17S)-11-(4-dimethylaminophenyl)-17-hydroxy-17-(3-hydroxypropyl)-13-methyl-1,2,6,7,8,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-3-one; Estra-4,9-dien-3-one, 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(3-hydroxypropyl)-, (11-beta,13-alpha,17-alpha)-

Indication

Disease Entry	ICD 11	Status	REF
Breast cancer	2C60-2C65	Phase 2	[1]
------------------------------------------------------------------------------------

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

List of Combinatorial Drugs (CBD) Containing This Drug

2 Clinical Trial Drug Combination(s) Consisting of This drug

DrugCom Name	DrugCom ID	Component Drug	Indication	REF
ABIRATERONE + Onapristone	DCHLJ9E	ABIRATERONE	Prostate Cancer	[2]
RAD-1901 + Onapristone	DCC8W8G	RAD-1901	Breast Cancer	[3]
------------------------------------------------------------------------------------

References

1	Clinical pipeline report, company report or official report of Context Therapeutics.
2	ClinicalTrials.gov (NCT02049190) Phase 1-2 Study of Onapristone in Patients With Advanced Castration-resistant Prostate Cancer
3	ClinicalTrials.gov (NCT05618613) Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer